Journal article
High betatrophin in coronary patients protects from cardiovascular events
Atherosclerosis, v 293, pp 62-68
Jan 2020
PMID: 31862484
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Betatrophin, also known as angiopoietin-like protein 8 (ANGPTL8) or lipasin, is a nutritionally-regulated mammalian-specific protein secreted by the liver and adipose tissue. Many conflicting data exist with respect to its association with type 2 diabetes mellitus (T2DM), insulin resistance, and lipid markers, but no data are available on its association with cardiovascular risk.
We measured betatrophin in 553 coronary patients undergoing coronary angiography for the evaluation of established or suspected stable coronary artery disease (CAD) and prospectively recorded cardiovascular events during a follow-up of up to 8 years.
During follow-up, 201 patients suffered a cardiovascular event and 64 died from cardiovascular causes. High betatrophin (upper tertile) was significantly and inversely associated with cardiovascular events both univariately (HR = 0.64 [95%CI 0.47–0.87], p = 0.004) and after full adjustment including the status of CAD and T2DM (adj. HR = 0.55 [95%CI 0.40–0.76], p < 0.001). The inclusion of betatrophin into a basic prediction model for the cardiovascular event risk significantly improved the model performance (NRI = 0.728, p < 0.001).
This study is the first to show that betatrophin predicts cardiovascular events independently of conventional risk factors including the presence of CAD and T2DM.
[Display omitted]
•Betatrophin was measured in 553 coronary patients.•Cardiovascular events were followed for up to 8 years.•High betatrophin protects from cardiovascular events and death.•Betatrophin was not associated with the presence or extent of atherosclerosis.
Metrics
Details
- Title
- High betatrophin in coronary patients protects from cardiovascular events
- Creators
- Andreas Leiherer (Corresponding Author) - Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, AustriaJanine Ebner - Vorarlberg Institute for Vascular Investigation and TreatmentAxel Muendlein - Vorarlberg Institute for Vascular Investigation and TreatmentEva M. Brandtner - Vorarlberg Institute for Vascular Investigation and TreatmentChristina Zach - Vorarlberg Institute for Vascular Investigation and TreatmentKathrin Geiger - Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, AustriaPeter Fraunberger - Private University of the Principality of Liechtenstein, Triesen, LiechtensteinHeinz Drexel - Drexel University, College of Medicine
- Publication Details
- Atherosclerosis, v 293, pp 62-68
- Publisher
- Elsevier B.V
- Number of pages
- 7
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:000506889300009
- Scopus ID
- 2-s2.0-85076480036
- Other Identifier
- 991021860772004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Cardiac & Cardiovascular Systems
- Peripheral Vascular Disease